Parte, Capitolo, Paragrafo
1 Intro, 0,0(1)| N., The potential supply of organ donors; an assessment
2 Intro, 0,0(1)| organ donors; an assessment of the efficacy of organ procurement
3 Intro, 0,0(1)| assessment of the efficacy of organ procurement efforts
4 I, 1,1(5) | Xeno-transplantation. The Transplantation of Organs and Tissues Between
5 I, 1,1(6) | Rinaldo CR JR., Detection of infectious baboon cytomegalovirus
6 I, 1,1(7) | xenotransplantation – A brief review of the world experience. In:
7 I, 1,1(7) | Xeno-transplantation. The Transplantation of Organs and Tissues Between
8 I, 1,1(9) | Xeno-transplantation. The Transplantation of Organs and Tissues Between
9 I, 1,1(10) | al., Long-term survival of nonhuman primates receiving
10 I, 1,1(10) | function for over one month of a transgenic porcine heart
11 I, 1,1(10) | al., Three-month survival of HDAF transgenic pig hearts
12 I, 1,1(10) | model system for the study of discordant xenotransplantation,
13 I, 1,1(10) | Byrne G.W., et al., The role of antibodies in acute vascular
14 I, 1,1(10) | acute vascular rejection of pig-to-primate cardiac transplants.
15 I, 2,2(14) | et al., Immunopathology of hyperacute xenograft rejection
16 I, 2,2(14) | R.J., et al., Mechanisms of complement activation in
17 I, 2,2(14) | the hyperacute rejection of porcine organs transplanted
18 I, 2,2(15) | et al., Identification of carbohydrate structures
19 I, 2,2(16) | Fryer J.P., et al., Removal of baboon and human antiporcine
20 I, 2,2(16) | immunoadsorption: Results of in vitro and in vivo studies,
21 I, 2,2(16) | Rose A.G., et al., Effects of cyclosporine and antibody
22 I, 2,2(16) | Havaux X., et al., Depletion of IgM xenoreactive natural
23 I, 2,2(16) | antibodies by injection of anti-mu monoclonal antibodies,
24 I, 2,2(16) | Studies on the removal of anti-pig xenoantibodies
25 I, 2,2(17) | Finstad J., et al., Role of the complement system in
26 I, 2,2(17) | R.R., et al., The effect of soluble complement receptor
27 I, 2,2(17) | on hyperacute rejection of porcine xenografts, Transplantation
28 I, 2,2(17) | and in vivo investigation of anticomplement agents FUT-175
29 I, 2,2(17) | K76COOH, in the prevention of hyperacute rejection following
30 I, 2,2(17) | injury in an ex vivo model of pit-to-human xenotransplantation,
31 I, 2,2(18) | L., Bach F:H., Inhibition of complement mediated endothelial
32 I, 2,2(18) | Potential for prevention of xenograft hyperacute rejection,
33 I, 2,2(19) | model system for the study of discordant xenotransplantation,
34 I, 2,2(19) | White D.J.G., The generation of transgenic pigs as potential
35 I, 2,2(19) | L.A., et al., Expression of a functional human complement
36 I, 2,2(19) | model for the prevention of xenogeneic hyperacute organ
37 I, 2,2(19) | gene transfer: production of pigs transgenic for a human
38 I, 2,2(19) | transgenic for a human regulator of complement activation, Transplant
39 I, 2,2(20) | al., Enzymatic remodeling of the carbohydrate surface
40 I, 2,2(20) | the carbohydrate surface of a xenogenic cell substantially
41 I, 2,2(21) | K., et al., Pathogenesis of and potential therapies
42 I, 2,2(23) | al., Long-term survival of nonhuman primates receiving
43 I, 2,2(23) | function for over one month of a transgenic porcine heart
44 I, 2,2(27) | M., et al., Modification of vascular responses in xenotransplantation:
45 I, 2,3(28) | K., et al., Pathogenesis of and potential therapies
46 I, 2,3(28) | al., Prolonged Survival of Hamster to Rat Heart xenografts
47 I, 2,3(29) | al., Prolonged Survival of Hamster to Rat Heart xenografts
48 I, 2,3(31) | survive in the presence of anti-donor antibodies and
49 I, 2,3(31) | that precipitate rejection of naive xenografts, J Immunol.
50 I, 2,3(33) | al., Long-term survival of nonhuman primates receiving
51 I, 2,3(33) | function for over one month of a transgenic porcine heart
52 I, 2,3(34) | Langford G.A. et al., Effect of transgenic expression of
53 I, 2,3(34) | of transgenic expression of human decay-accelerating
54 I, 2,3(34) | factor on the inhibition of hyperacute rejection of
55 I, 2,3(34) | of hyperacute rejection of pig organs. In: Cooper DKC,
56 I, 2,3(34) | Xeno-transplantation. The Transplantation of Organs and Tissues Between
57 I, 2,3(35) | al., Long-term survival of nonhuman primates receiving
58 I, 2,3(35) | al., Three-month survival of HDAF transgenic pig hearts
59 I, 2,3(36) | al., Three-month survival of HDAF transgenic pig hearts
60 I, 2,3(37) | function for over one month of a transgenic porcine heart
61 I, 2,3(38) | al., Long-term survival of nonhuman primates receiving
62 I, 2,4(39) | approach to the control of disease transmission in
63 I, 2,4(40) | Talbot T., Definition of a production Specification
64 I, 2,4(41) | retroviruses, and the evolution of retroelements, Chapter 8
65 I, 2,4(42) | Weiss RA, 1997, Infection of human cells by an endogenous
66 I, 2,4(42) | an endogenous retrovirus of pigs. Nature Med 3:282-286. ~
67 I, 2,4(43) | cross-species transmission of porcine endogenous retrovirus
68 I, 2,5(44) | cloning by microinjection of fetal fibroblast nuclei,
69 I, 2,5(45) | C.T., Inducible control of gene expression: prospects
70 I, 3,6(46) | et al., Transplantation of Porcine fetal pancreas to
71 I, 3,6(48) | L.M., Mullon C., Overview of extracorporeal liver support
72 I, 3,6(48) | Functional evaluation of the AMC-BAL to be employed
73 I, 3,6(49) | Brink J., et al., Report of the xenotransplantation
74 I, 3,6(49) | xenotransplantation advisory committee of the international society
75 I, 3,6(49) | transplantation. The present status of xenotransplantation and
76 I, 3,6(49) | potential role in the treatment of end-stage cardiac and pulmonary
77 I, 3,6(50) | al., Long-term survival of nonhuman primates receiving
78 I, 3,6(50) | function for over one month of a transgenic porcine heart
79 I, 3,6(50) | al., Three-month survival of HDAF transgenic pig hearts
80 II, 2,12(65) | J., The Seductive Sirens of Medical Progress. The case
81 II, 2,12(65) | Medical Progress. The case of Xenotransplantation, Hastings
82 II, 2,12(65) | 25: 5-6; Nuffield Council of Bioethics, Animal-to-Human
83 II, 2,12(65) | Transplants: the Ethics of Xenotransplantation, London:
84 II, 2,12(65) | London: Nuffield Council of Bioethics, 1996; Mc Carthy
85 II, 2,12(65) | Transplantation, Kennedy Institute of Ethics Journal, 1996, 6:
86 II, 2,12(65) | 183-188; U.S. Institute of Medicine Committee on Xenograft
87 II, 2,12(65) | Ethical Issues, Journal of Medical Ethics, 1998, 24:
88 II, 2,12(65) | Xenozoonose Debate, Journal of Law, Medicine and Ethics,
89 II, 2,12(65) | R.P., Xeno, the Promise of Transplanting Animal Organs
90 II, 2,12(65) | issues concerning the use of Xenotransplantation products
91 II, 2,13(66) | T.W. (ed.), Encyclopedia of Bioethics, vol. 4, New York:
92 II, 2,14(68) | Starting Clinical Trials of Xenotransplantation. Reflections
93 II, 2,14(68) | Reflections on the Ethics of the Early Phase, J Med Ethics
94 II, 2,14(70) | G.M., Psychiatric Aspects of Organ Transplantation, New
95 II, 2,16(71) | consent and the assessment of infectious disease risks
96 II, 2,17(72) | economic and legal aspects of xenotransplantation, Law
97 II, 3,21(75) | in materia: the Council of Europe, the Health Council
98 II, 3,21(75) | Europe, the Health Council of the Netherlands, the Swedish
99 II, 3,21(75) | Xenotransplantation, the US Department of Health and Human Services
100 II, 3,21(75) | trials will need the approval of the newly formed Agency
101 II, 3,21(75) | Agency for the Security of Health Products and of the
102 II, 3,21(75) | Security of Health Products and of the Ministry of Health.
103 II, 3,21(75) | Products and of the Ministry of Health. In Germany, the
|